37 Fibromyalgia Clinical Trials in Birmingham, AL (2026)

Q: How do I join a clinical trial in Birmingham?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you.

Recruiting Fibromyalgia Studies in Birmingham

NCT01915511Recruiting

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to inc...

Birmingham, AL3,000 participantsDuke University

View Study Details

NCT06238622Recruiting

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medic...

Birmingham, ALPHASE31,700 participantsBoehringer Ingelheim

View Study Details

NCT05548283Recruiting

Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or I...

Birmingham, ALPHASE4730 participantsChris Goss

View Study Details

NCT05943535Recruiting

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period....

Birmingham, ALPHASE3698 participantsUnited Therapeutics

View Study Details

NCT06479135Recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptim...

Birmingham, ALPHASE3600 participantsKartos Therapeutics, Inc.

View Study Details

NCT03161808Recruiting

Rare CFTR Mutation Cell Collection Protocol (RARE)

Over 1,900 mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein are implicated in causing Cystic Fibrosis (CF). Potential therapies that directly target def...

Birmingham, AL500 participantsGeorge Solomon

View Study Details

NCT06654752Recruiting

Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for t...

Birmingham, ALNA430 participantsUniversity of Washington, the Collaborative Health Studies Coordinating Center

View Study Details

NCT06504589Recruiting

A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

The REACH study is for people with CF who do not take cystic fibrosis transmembrane conductance regulator (CFTR) modulators. The goal of the REACH study is to collect research data, including health d...

Birmingham, AL400 participantsNicole Hamblett

View Study Details

NCT06806592Recruiting

A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study. People can only take part if they show no improve...

Birmingham, ALPHASE3400 participantsBoehringer Ingelheim

View Study Details

NCT07652658Recruiting

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nint...

Birmingham, ALPHASE2359 participantsAstraZeneca

View Study Details

NCT06951217Recruiting

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

This is an open-label extension study for participants who were previously enrolled in and completed an Avalyn Pharma Sponsored study with an inhaled antifibrotic, such as AP01. Eligible participants ...

Birmingham, ALPHASE2340 participantsAvalyn Pharma Inc.

View Study Details

NCT06559150Recruiting

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebuli...

Birmingham, ALPHASE2284 participantsVerona Pharma plc

View Study Details

NCT06595420Recruiting

Kidney Function in People With Cystic Fibrosis in the Era of HEMT

The purpose of this study is to find out what causes kidney disease in people with CF. The investigators will study biomarkers in the blood and urine that can either predict who is at risk or detect k...

Birmingham, AL260 participantsUniversity of Virginia

View Study Details

NCT04176198Recruiting

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or...

Birmingham, ALPHASE1240 participantsSumitomo Pharma America, Inc.

View Study Details

NCT04509050Recruiting

Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children

This is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact on children wit...

Birmingham, AL210 participantsSonya Heltshe

View Study Details

NCT06188741Recruiting

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

Plexiform neurofibromas (PN) are known to cause significant morbidity in children with NF1. The recent FDA approval for selumetinib in children 2 years and older with inoperable symptomatic PN was bas...

Birmingham, ALPHASE2200 participantsUniversity of Alabama at Birmingham

View Study Details

NCT06837181Recruiting

Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)

This multicenter cross-sectional study will include a diverse population of adolescents and adults with CF. The overall Aim is to describe prevalence of diabetes microvascular complications and macro...

Birmingham, AL200 participantsJaeb Center for Health Research

View Study Details

NCT06683092Recruiting

Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having exp...

Birmingham, AL200 participantsBoston Children's Hospital

View Study Details

NCT07230288Recruiting

Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF) is a rare, long-lasting lung disease that causes scarring of lung tissue, shortness of breath, and loss of lung function. IPF leads to significant loss of quality o...

Birmingham, ALPHASE2165 participantsAbbVie

View Study Details

NCT06967805Recruiting

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)...

Birmingham, ALPHASE2164 participantsMediar Therapeutics

View Study Details

NCT06296394Recruiting

Health Outcomes of Parents With Cystic Fibrosis-Aim 2

The goal of this observational prospective study is to determine the health impact of parenthood on United States (US) people with CF in the era of CF transmembrane regulator protein (CFTR) modulators...

Birmingham, AL146 participantsUniversity of Pittsburgh

View Study Details

NCT03759522Recruiting

Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.

The primary objective of this study is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET radiopharmaceutical \[F-18\]DPA-714 in in...

Birmingham, ALPHASE1120 participantsUniversity of Alabama at Birmingham

View Study Details

NCT06968845Recruiting

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Rationale: LTI-03 is an experimental medication breathed into the lungs using an inhaler. It is being studied for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive, fatal lung...

Birmingham, ALPHASE2120 participantsRein Therapeutics

View Study Details

NCT07148739Recruiting

Ensuring Access to Optimal Therapy in CF: The ENACT Study

This clinical trial is examining the action and effects of several new drugs in the treatment of cystic fibrosis in children. In addition, several genetic factors are examined. The hope is that the ab...

Birmingham, ALPHASE4100 participantsArkansas Children's Hospital Research Institute

View Study Details

NCT04002882Recruiting

Role of Body Fat Distribution in Metabolic and Pulmonary Decline in Cystic Fibrosis (ORBIT-CF)

Nutrition and body composition, the amount of muscle and fat in the body, has a role in overall health. This study wants to learn more about how nutrition and body composition affects health outcomes ...

Birmingham, AL90 participantsEmory University

View Study Details

NCT07036523Recruiting

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

This study is open to adults who are at least 40 years old and have idiopathic pulmonary fibrosis (IPF). People can participate in the study if they have a forced vital capacity (FVC) greater than or ...

Birmingham, ALPHASE271 participantsBoehringer Ingelheim

View Study Details

NCT05280509Recruiting

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or P...

Birmingham, ALPHASE170 participantsTelios Pharma, Inc.

View Study Details

NCT06998043Recruiting

Study With Phage for CF Subjects With Pseudomonas Lung Infection

The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects. The primary goal is to see if 8 weeks of twi...

Birmingham, ALPHASE263 participantsBiomX Ltd

View Study Details

NCT06574165Recruiting

Relationships of Affect and Neuroinflammation With Clinical Pain in Veterans With Fibromyalgia

Fibromyalgia (FM) is a chronic pain condition that disproportionately impacts Veterans. Individuals diagnosed with FM patients experience lower self-esteem and positive affect, as well as greater leve...

Birmingham, ALNA60 participantsVA Office of Research and Development

View Study Details

NCT07031323Recruiting

OnTrackCF: Engagement, Feasibility, and Acceptability Study

This is a multi-site, nonrandomized study using mixed methods approach to evaluate the feasibility, acceptability, and user engagement of OnTrackCF for adults with Cystic Fibrosis (AWCF)....

Birmingham, ALNA60 participantsBoston Children's Hospital

View Study Details

NCT05975983Recruiting

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

The goal of this clinical trial is to learn about INS018\_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018\_055 orall...

Birmingham, ALPHASE240 participantsInSilico Medicine Hong Kong Limited

View Study Details

NCT05068791Recruiting

Psilocybin-facilitated Treatment for Chronic Pain

The primary purpose of this study is to preliminarily estimate the efficacy of psilocybin-facilitated treatment for fibromyalgia. Investigators will assess the impact of psilocybin-facilitated treatme...

Birmingham, ALEARLY_PHASE130 participantsUniversity of Alabama at Birmingham

View Study Details

NCT05248230Recruiting

4D-710 in Adult Patients With Cystic Fibrosis

This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis....

Birmingham, ALPHASE230 participants4D Molecular Therapeutics

View Study Details

NCT06502171Recruiting

Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas

Based on the clinical activity of both selumetinib and cabozantinib as monotherapies in clinical trials, the demonstrated activity of these agents in reduced doses in preclinical studies, and the non-...

Birmingham, ALPHASE130 participantsGirish Dhall, MD

View Study Details

NCT06541847Recruiting

A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1

The trial will be an open label, single arm, phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years of age or older with pr...

Birmingham, ALPHASE225 participantsHealx Limited

View Study Details

NCT03587961Recruiting

Personalized Theratyping Trial

The purpose of this study is to explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs....

Birmingham, ALEARLY_PHASE120 participantsGeorge Solomon

View Study Details

NCT04362644Recruiting

Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose (\[18F\] FDG) and fluorine-18 Displacement Per Atom (\[18F\]DPA-714) using positron emission tomography and computed t...

Birmingham, ALPHASE110 participantsUniversity of Alabama at Birmingham

View Study Details

About Fibromyalgia Clinical Trials in Birmingham

Fibromyalgia is a condition characterized by widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive difficulties. It affects about 2-4% of the population, predominantly women. Treatment includes medications, exercise, stress management, and cognitive behavioral therapy.

There are currently 37 fibromyalgia clinical trials recruiting participants in Birmingham, AL. These studies are seeking a combined 12,165 participants. Research is being sponsored by Duke University, Boehringer Ingelheim, Chris Goss and 27 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Fibromyalgia Clinical Trials in Birmingham — FAQ

Are there fibromyalgia clinical trials in Birmingham?

Yes, there are 37 fibromyalgia clinical trials currently recruiting in Birmingham, AL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Birmingham?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you about next steps.

Are clinical trials in Birmingham free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Birmingham studies also compensate for your time and travel.

What fibromyalgia treatments are being tested?

The 37 active trials in Birmingham are testing new therapies including novel drugs, biologics, and treatment approaches for fibromyalgia.

Data updated August 28, 2026 from ClinicalTrials.gov